Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome

[1]  N. Shah,et al.  Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Cerhan,et al.  2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.

[3]  R. Bindra,et al.  Adjuvant chemotherapy and overall survival in adult medulloblastoma , 2016, Neuro-oncology.

[4]  L. Wilson,et al.  Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non–Small-Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  S. Hung,et al.  Higher caseload improves cervical cancer survival in patients treated with brachytherapy , 2014, Radiation oncology.

[6]  L. Wilson,et al.  Poorer prognosis of African-American patients with mycosis fungoides: an analysis of the SEER dataset, 1988 to 2008. , 2014, Clinical lymphoma, myeloma & leukemia.

[7]  M. Beyer,et al.  Systematic review of combination therapies for mycosis fungoides. , 2014, Cancer treatment reviews.

[8]  M. Krasnik,et al.  High procedure volume is strongly associated with improved survival after lung cancer surgery. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Holmberg,et al.  Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004–2008 , 2012, Gut.

[10]  E. Ward,et al.  Insurance status and racial differences in uterine cancer survival: a study of patients in the National Cancer Database. , 2011, Gynecologic oncology.

[11]  J. Scarisbrick,et al.  Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Amy Y. Chen,et al.  Improved survival is associated with treatment at high‐volume teaching facilities for patients with advanced stage laryngeal cancer , 2010, Cancer.

[13]  Nicola Pimpinelli,et al.  WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects , 2005, Journal of cutaneous pathology.

[14]  M. Gonen,et al.  Long-Term Survival Is Superior After Resection for Cancer in High-Volume Centers , 2005, Annals of surgery.

[15]  S. Mehta,et al.  Role of surgeon volume in radical prostatectomy outcomes. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. McCalmont,et al.  Mycosis fungoides: the great imitator. , 2002, Journal of the American Academy of Dermatology.

[17]  C. Begg,et al.  The influence of hospital volume on survival after resection for lung cancer. , 2001, The New England journal of medicine.

[18]  U. Hipler,et al.  Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. , 2001, Journal of the American Academy of Dermatology.

[19]  A. Varghese,et al.  Clinical Characteristics and Outcome of Patients With Extracutaneous Mycosis Fungoides , 2001 .

[20]  T. Petrella,et al.  Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. , 2000, Blood.

[21]  R. Kurzrock,et al.  Prognostic factor analysis in mycosis fungoides/Sézary syndrome. , 1999, Journal of the American Academy of Dermatology.

[22]  R. Kurzrock,et al.  Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. , 1998, Blood.

[23]  E. Partridge,et al.  The National Cancer Data Base: Ten years of growth and commitment , 1998, CA: a cancer journal for clinicians.

[24]  L. Wilson,et al.  Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy , 1996, Cancer.

[25]  L. Wilson,et al.  Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation. , 1995, Archives of dermatology.

[26]  C. Gisselbrecht,et al.  Mycosis fungoides and the Sézary syndrome. , 1993, Nouvelle revue francaise d'hematologie.

[27]  E. Vonderheid,et al.  Infections complicating mycosis fungoides and Sézary syndrome. , 1992, JAMA.

[28]  Z. Fuks,et al.  Total-skin electron treatment of mycosis fungoides. , 1971, Radiology.

[29]  B. Thiers.  Folliculotropic Mycosis Fungoides: An Aggressive Variant of Cutaneous T-Cell Lymphoma , 2009 .

[30]  C. Meijer,et al.  Lymph node classification systems in cutaneous T‐cell lymphoma. Evidence for the utility of the working formulation of non‐Hodgkin's lymphomas for clinical usage , 1994, Cancer.